https://www.chinahealthreport.com/article/907007986-junshi-biosciences-presents-results-from-js207-pd-1-vegf-bsab-phase-2-combo-studies-and-js212-egfr-her3-adc-fih-phase-1-2-study-at-aacr-2026 China Health Report en PressRelease 2026-04-20T21:00:00+00:00 Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026 https://ml.globenewswire.com/media/815f9c91-bb76-4c14-b3e9-0685275600cc/small/junshi-topalliance-logo-png.png